| (Values in U.S. Thousands) | Dec, 2022 | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | 0 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Inyx Inc (IYXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
INYX, INC. is a provider of specialty pharmaceutical products and technologies. Its operations are focused on the development of both prescriptions, over the counter pharmaceutical products, and specialty consulting services. Also, the Company utilizes niche drug delivery capabilities to develop its own products. The product and service categories of the Company include Metered Dose Inhalers, Dry Powder Inhalers. Metered Dose Pump Sprays, Hydrocarbon Foam Aerosols, Saline Aerosols, Sterile Solutions/Injectables, Solid Dose, Formulation Services, Analytical Development Validation, Stability Services, Regulatory Support and Integrated Project Management.
Fiscal Year End Date: 12/31